Dr. Cho is a trained behavior scientist and clinical epidemiologist. Her primary research interests are the psycho-social problems caused by cancer and its treatment. Dr. Cho is leading several qualitative and quantitative observational studies and clinical trials to find out the needs of cancer patients and their families, as well as to develop and implement the education programs both in clinic and in communities. As part of her work, she has had to develop or validate a variety of patient-reported outcome (PRO) measures for survivorship and health-related quality of life for cancer survivors in Korea and other Asian countries. She is active member of PROMIS Health Organization and currently responsible for PROMIS National Center in Korea.

Dr. Cho is also expert in research methods for digital therapeutics and conducting studies with SaMD and medical devices as well. She is advisory member for Digital Technologies Advisory board at Korean FDA. 

Dr. Cho is currently the Director of Cancer Education Division at the Samsung Comprehensive Cancer Center, Director of Center for Clinical Epidemiology at Samsung Medical Center, and the Chair of the Department of Clinical Research Design and Evaluation at SAIHST, Sungkyunkwan University, Seoul, Korea. She also adjunct professor at Johns Hopkins Bloomberg School of Public Health, Balitmore, MD, USA.

Manager at DG Daiwa Ventures, a global VC based in Tokyo, specializing in healthcare and climate tech investments. Previously worked at Sumitomo Corporation, actively involved in supporting investments into infrastructure projects for Asian and African governments. Transitioned to the London office, engaged in M&A and post-merger integration in automotive, chemical, and logistics sectors. Joined DG Daiwa Ventures in Oct 2021, focusing on healthcare after witnessing the medical collapse during the pandemic. Notable investments include Akili, Limbix, Intellect, Allara, WHILL, and Winterlight etc.